ABSTRACT
INTRODUCTION
Open-angle glaucoma (OAG) is associated with progressive visual field damage and visual function loss that can lead to disability and adversely affect health-related quality of life [1] [2] [3] [4] . Ocular hypertension (OHT) is considered a key risk factor for primary OAG, and reducing intraocular pressure (IOP) and maintaining target IOP can delay or prevent the onset of primary OAG in patients with OHT and slow disease progression in patients with glaucoma [5] [6] [7] [8] [9] [10] . Accordingly, recommended goals of treatment for patients with OAG and those with OHT at risk of developing OAG include maintaining IOP within a target range and achieving stability of the optic nerve/retinal nerve fiber layer status and of visual fields [11, 12] . A desirable IOP range should be determined for each patient based on a goal of minimizing the impact of visual field loss on quality of life; the upper limit of this range is considered the ''target pressure'' for achieving the sought after clinical goals. Lowering of IOP by 25% is a well-documented benchmark for slowing the progression of primary OAG, but even more aggressive targets may be appropriate in some patients depending on disease severity and other risk factors [11] [12] [13] .
Topical prostaglandin analogs are potent ocular hypotensive agents with good IOP-lowering efficacy and a favorable safety profile [14, 15] . Common ocular side effects of topical prostaglandin receptor agonists include conjunctival hyperemia, elongation and darkening of eyelashes, iris pigmentation changes, and periocular skin hyperpigmentation [16] [17] [18] [19] . While these agents are [29, 30] . Preclinical and clinical studies suggest that both active moieties of LBN (latanoprost acid and NO) contribute to its potent IOP-lowering effect [21, 22, 29] . In animal models of OHT or glaucoma, LBN produced significantly greater reductions in IOP than equimolar concentrations of latanoprost [21] . In a study using prostanoid FP-receptor knockout mice, LBN administration lowered IOP from 0.45 to 1.23 mmHg, while latanoprost had no effect, providing evidence to support a distinct pharmacologic activity of NO [31] . Safety assessments included treatmentemergent adverse events (AEs), vital signs, corrected decimal VA, conjunctival hyperemia assessment, slit-lamp examination findings, ophthalmoscopy findings, photographs of the irides, eyelids, and eyelashes, visual field assessment, gonioscopy, and pachymetry. VA was measured at baseline and all study visits using a decimal VA chart. The investigator graded conjunctival hyperemia prior to slit-lamp examination and IOP measurement on a scale of 1-4 using photographic standards (1 = none, 4 = severe). Photographs were taken using a slit-lamp mounted digital camera at Visits 3 (Day 0) and 16 (week 52), and were evaluated at the end of the study to assess any changes. Iris pigmentation was graded using four categories (1 = no increase, 2 = undecided, 3 = possible increase, and 4 = clear increase) by an independent reviewer, whereas any change in eyelid pigmentation or eyelashes was evaluated by the investigator and reported as an AE.
IOP was assessed at screening, the mid-washout visit (if applicable), baseline, and at each post-baseline study visit in both eyes at 10 AM ± 30 min using a Goldman applanation tonometer. For each patient, IOP was measured by the same operator using the same tonometer at each visit whenever possible.
Endpoints
Efficacy endpoints were absolute IOP values and reduction from baseline (RFB) in IOP. Safety endpoints included AEs, vital signs, corrected decimal VA, conjunctival hyperemia assessment, slit-lamp examination, ophthalmoscopy, photographs, visual field assessment, gonioscopy, and pachymetry.
Statistical Analysis
The sample size of 130 subjects was not based on power considerations for testing any hypothesis and was assumed to provide sufficient data to study the safety profile of LBN 0.024% QD over 52 weeks using descriptive statistics.
Treatment adherence was defined as the percentage of prescribed instillations received (based on diary card entries).
Safety analyses were based on the safety population, which included all subjects who received at least one dose of study drug. Treatment-emergent AEs were coded using Medical Dictionary for Regulatory Activities, version 16.0 and summarized by severity and relationship to study drug. Treatment-emergent ocular AEs were summarized for study eyes and treated fellow eyes, and treatment-emergent non-ocular AEs were summarized at the subject level by system organ class and preferred term.
Vital sign measurements and visual acuity were summarized using descriptive statistics.
Conjunctival hyperemia was categorized as none, mild, moderate, and severe, with the number and percentage of subjects in each category presented by visit. The number and percentage of subjects having C1 hyperemia and C1 moderate or severe hyperemia were also presented by visit. Iris photographs from Visits Efficacy analyses were based on the safety population (all subjects who received at least 1 dose of study drug). The absolute IOP, RFB in IOP, and mean percent change from week 4 through week 52 were summarized for study eyes and treated fellow eyes at each visit using descriptive statistics and discrete summaries (proportion of subjects with RFB in IOP C5 and C10 mmHg; proportion of subjects with RFB in IOP at each visit categorized into: B-5, -4 to 0, 1-4, 5-9, 10-14, and C15 mmHg). In addition, a paired t test was performed on the RFB at each visit.
In general, continuous variables were summarized by sample size, mean, standard deviation (SD), median, minimum, and maximum. Summaries for discrete variables included the tabulation of frequencies and percentages. All statistical analyses were performed using the SAS software (SAS Institute, Cary, NC, USA) version 9.2 or higher.
RESULTS

Subjects
A total of 151 subjects were screened. Of these, 130 subjects were enrolled and 121 (93.1%) completed the study. Reasons for study discontinuation included AEs (n = 4), withdrawal of consent (n = 4), and investigator decision (n = 1).
The mean (SD) age of the study population was 62.5 (18.9) years (range 39-81 years); the median age was 64.0 years. A slightly higher percentage of subjects was female than male (56.9% vs. 43.1%), and all subjects were Japanese. The majority of subjects (90.0%) were on prior IOP-lowering medication at screening and required a washout. In all but four subjects, both eyes qualified for treatment. Treatment-related ocular AEs were those categorized as possibly, probably, or definitely related to treatment AE treatment-emergent adverse event, LBN latanoprostene bunod a Reported as an AE (see Table 2 for investigator assessments of hyperemia) large intestine polyp, breast cancer) were classified after the subject ended study participation. The serious AE of vestibular neuronitis was considered severe in intensity, whereas all other serious AEs were considered mild or moderate in severity. None of the serious AEs were considered by the investigator to be related to study treatment.
No treatment-related changes in blood pressure or heart rate were observed from baseline through week 52. Two subjects had vital sign measurements that were associated with AEs (mild hypertension) considered to be not or unlikely related to study drug.
Mean decimal VA at baseline was 1.11 in the study eye and 1.13 in the treated fellow eye. For all post-baseline study visits, the mean decimal VA ranged from 1.10 to 1.13 for the study eye and 1.10-1.15 for the treated fellow eye.
The incidence of conjunctival hyperemia as assessed by investigators is summarized in Table 2 by visit and severity. At baseline, prior to treatment, mild hyperemia was present in 20 (15.4%) study eyes and 18 (14.3%) treated fellow eyes. At the week 4 and week 8 visits, mild hyperemia was noted in additional 6 or 7 eyes in each group. The proportion of eyes with hyperemia remained low; at the 52 week visit, LBN latanoprostene bunod a There were no instances of severe hyperemia in any treated eye during the study b Data missing for the study eye and the treated fellow eye for one subject at week 8; two subjects at week 12; four subjects at weeks 16, 20, 24, and 28; five subjects at week 32; seven subjects at week 36; eight subjects at weeks 40, 44, and 48; and nine subjects at week 52 the number of eyes with hyperemia was only 2 higher than at baseline in both the study eye and treated fellow eye groups. From week 12 on, there were 1 or 2 eyes in each group with moderate hyperemia; all other cases were mild. No subjects had severe conjunctival hyperemia at any visit during the study.
Abnormal biomicroscopy findings for the lid, conjunctiva bulbi, the conjunctiva palpebrae, the cornea, and the anterior chamber were rare in both study eyes and treated fellow eyes and showed no consistent patterns. The number of eyes with abnormal findings for these assessments either stayed the same or increased or decreased by 1 or 2 subjects at each study visit. The number of study and Ophthalmoscopy findings indicated no changes in the number of subjects with abnormalities in the vitreous body, the retina, the macula, the choroid, the optic nerve, or the mean cup/disc vertical ratio in the study eye or the treated fellow eye after 52 weeks of treatment with LBN 0.024%. At baseline, optic disc hemorrhage was evident in one study eye and two treated fellow eyes; at week 4, the presence of optic disc hemorrhage was unchanged among study eyes and decreased by one subject at week 4 in treated fellow eyes. Missing assessments precluded evaluation of optic disc hemorrhage at subsequent visits. At baseline, rim loss was noted in 19 (14.6%) of study eyes and 13 (10.3%) of treated fellow eyes, and retinal nerve fiber layer defects were observed in 13 (10.0%) of study eyes and 6 (4.8%) of treated fellow eyes. There were no changes in the number of eyes with these findings at any study visit, and no notable results from visual field assessment, gonioscopy, or pachymetry.
Efficacy
The mean (SD) IOP at each visit from baseline to week 52 for the study eye and the treated fellow eye for all subjects is shown in Fig. 2 , and the RFB in IOP from baseline to each study visit is shown in Fig. 3 . In the study eye, a 22.0% reduction in IOP to 15.3 (3.0) mmHg was achieved by week 4, and reductions greater than 22% were observed at every subsequent visit. Similarly, a 19.5% reduction in IOP to 15.0 (2.8) mmHg was achieved by week 4 in the treated fellow eye, and reductions of more than 20% were seen at every visit after week 4. At week 52, the percent reductions in IOP were 26.3% and 23.0% in study eyes and treated fellow eyes, respectively, to 14.4 (2.7) mmHg in both eyes. For both the study eye and the treated fellow eye, the reductions from baseline were statistically significant (P\0.001) at every study visit from week 4 through week 52.
At weeks 4 and 8, 42.3% and 48.1%, respectively, of subjects had an RFB in IOP of C5 mmHg for the study eye. Between 52.3% and 64.2% of subjects had a reduction in IOP of C5 mmHg for the study eye from week 12 to week 52. From weeks 8 to 20, between 42.4% and 47.5% of subjects had a reduction in IOP of C5 mmHg in the treated fellow eye. Reductions in IOP of C5 mmHg were observed in the treated fellow eye for 50.0-54.2% of subjects at weeks 24 and 28 and weeks 36-48, whereas at week 52, 48.7% of subjects had a reduction in IOP of C5 mmHg in the treated fellow eye.
DISCUSSION
This multicenter, open-label study in Japanese subjects with OAG or OHT was designed to evaluate the long-term safety and IOP-lowering efficacy of LBN ophthalmic solution 0.24% QD. The study treatment duration of 12 months is [19, 39] . In the current study, iris hyperpigmentation was reported as an AE in 4% of treated eyes, and, at 1 year, an increase in iris pigmentation was noted in 9% of treated eyes and a possible increase was noted in another 14% based on iris photographs. Iridial pigmentation changes have also been reported with latanoprost in clinical studies with Japanese subjects [40] [41] [42] [43] . These studies found the incidence of iris pigmentation to increase in proportion to duration of latanoprost treatment, with reported frequencies at 1 year ranging from 51.6% [42] to 58.2% [43] based on slit-lamp biomicroscopy, a rate much higher than that found in the current study with LBN. However, another 1-year study of latanoprost in 124 Japanese patients with primary OAG or OHT reported iris hyperpigmentation in only ten patients [44] .
Reducing IOP is the primary modifiable factor in managing patients with, or at risk for, glaucoma. Expert consensus guidelines suggest that gold standard pharmacologic glaucoma therapy is defined by the long-term control of IOP with no induction of tachyphylaxis or tolerance [45] . Tachyphylaxis Japanese populations are known to have lower
IOPs compared with non-Asian groups, and NTG is a common finding [54] . The current study population included subjects with NTG, and the majority of eyes had a baseline IOP between 15
and 21 mmHg. As in high-pressure glaucoma, the reduction of IOP has been shown to slow visual field damage in NTG [9, 55] and may minimize progression of the disease [56] [57] [58] . A prior study of [33, 35] .
Furthermore, the IOP lowering with LBN was maintained through the open-label phase of these studies [63] .
CONCLUSION
The results of this single-arm, multicenter, open-label, clinical study suggest that LBN ophthalmic solution 0.024% QD was safe and well-tolerated, with no significant AEs in Japanese subjects when used for up to 1 year.
In addition, the results demonstrated that the long-term treatment with LBN ophthalmic solution 0.024% provided significant and sustained reduction of IOP in Japanese subjects with a diagnosis of OAG or OHT. 
